Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients With Gout
NCT ID: NCT06887452
Last Updated: 2025-03-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
310 participants
INTERVENTIONAL
2026-03-01
2030-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluating the Effectiveness of a Chronic Disease Management Program for Gout
NCT01568879
Virtual Gout Clinic
NCT02790463
Treat-to-target by Email During Urate-lowering Therapy in Gout
NCT04733079
Study of URC102 to Assess the Safety and Efficacy in Gout Patients
NCT02557126
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
NCT06846515
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pharmacist-Led
Veterans will participate in regular telehealth visits with study pharmacists. Serum urate lab tests will be ordered during dose escalation phase of gout treatment.
Pharmacist-Led
Pharmacist will conduct regular telehealth visits with Veterans during dose escalation phase of gout treatment
Usual care
Veterans will receive standard care from their primary care provider for the management of their gout.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pharmacist-Led
Pharmacist will conduct regular telehealth visits with Veterans during dose escalation phase of gout treatment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Documented hyperuricemia (SU \>6.8 mg/dL)
* Satisfy ACR/EULAR gout classification criteria
* Report 1 or more flares in the prior 6 months
* Receipt of a new ULT prescription (allopurinol or febuxostat) initiated by a primary care provider or longer term ULT but otherwise satisfy the flare/SU criteria
Exclusion Criteria
* Patients with a rheumatology encounter within the prior 3 months
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
VA Office of Research and Development
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ted R. Mikuls
Role: PRINCIPAL_INVESTIGATOR
Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE
Omaha, Nebraska, United States
VA Portland Health Care System, Portland, OR
Portland, Oregon, United States
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Philadelphia, Pennsylvania, United States
VA Salt Lake City Health Care System, Salt Lake City, UT
Salt Lake City, Utah, United States
VA Puget Sound Health Care System Seattle Division, Seattle, WA
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CX002995
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
IMMA-005-24F
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.